Mutational Pathways, Resistance Profile, and Side Effects of Cyanovirin Relative to Human Immunodeficiency Virus Type 1 Strains with N-Glycan Deletions in Their gp120 Envelopes
- 1 September 2006
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 80 (17) , 8411-8421
- https://doi.org/10.1128/jvi.00369-06
Abstract
Limited data are available on the genotypic and phenotypic resistance profile of the α-(1-2)mannose oligomer-specific prokaryotic lectin cyanovirin (CV-N). Therefore, a more systematic investigation was carried out to obtain a better view of the interaction between CV-N and human immunodeficiency virus type 1 (HIV-1) gp120. When HIV-1-infected CEM cell cultures were exposed to CV-N in a dose-escalating manner, a total of eight different amino acid mutations exclusively located at N-glycosylation sites in the envelope surface gp120 were observed. Six of the eight mutations resulted in the deletion of high-mannose type N-glycans (i.e., at amino acid positions 230, 332, 339, 386, 392, and 448). Two mutations (i.e., at position 136 and 160) deleted a complex type N-glycan in the variable V1/V2 domain of gp120. The level of phenotypic resistance of the mutated virus strains against CV-N generally correlated with the number of glycan deletions in gp120, although deletion of the glycans at N-230, N-392, and N-448 generally afforded a more pronounced CV-N resistance than other N-glycan deletions. However, the extent of the decrease of antiviral activity of CV-N against the mutated virus strains was markedly less pronounced than observed for α(1-3)- and α(1-6)-mannose-specific plant lectins Hippeastrum hybrid agglutinin (HHA) and Galanthus nivalis agglutinin (GNA), which points to the existence of a higher genetic barrier for CV-N. This is in agreement with a more consistent suppression of a wider variety of HIV-1 clades by CV-N than by HHA and GNA. Whereas the antiviral and in vitro antiproliferative activity of CV-N can be efficiently reversed by mannan, the pronounced mitogenic activity of CV-N on peripheral blood mononuclear cells was unaffected by mannan, indicating that some of the observed side effects of CV-N are unrelated to its carbohydrate specificity/activity.Keywords
This publication has 30 references indexed in Scilit:
- Large-molecular-weight carbohydrate-binding agents as HIV entry inhibitors targeting glycoprotein gp120Current Opinion in HIV and AIDS, 2006
- Marked Depletion of Glycosylation Sites in HIV-1 gp120 under Selection Pressure by the Mannose-Specific Plant Lectins of Hippeastrum Hybrid and Galanthus nivalisMolecular Pharmacology, 2005
- Profile of Resistance of Human Immunodeficiency Virus to Mannose-Specific Plant LectinsJournal of Virology, 2004
- Site-specific Discrimination by Cyanovirin-N for α-Linked Trisaccharides Comprising the Three Arms of Man8 and Man9Journal of Molecular Biology, 2002
- Targeting glycosylation as a therapeutic approachNature Reviews Drug Discovery, 2002
- Solution Structure of a Cyanovirin-N:Manα1-2Manα ComplexStructure, 2001
- Crystal structure of cyanovirin-N, a potent HIV-inactivating protein, shows unexpected domain swappingJournal of Molecular Biology, 1999
- Solution structure of cyanovirin-N, a potent HIV-inactivating proteinNature Structural & Molecular Biology, 1998
- Analysis of Sequence Requirements for Biological Activity of Cyanovirin-N, a Potent HIV(Human Immunodeficiency Virus)-Inactivating ProteinBiochemical and Biophysical Research Communications, 1997
- Leaves of the Orchid Twayblade (Listera ovata) Contain a Mannose-Specific LectinPlant Physiology, 1987